ブルガダ症候群の世界市場

ブルガダ症候群の世界市場は2030年までに19億米ドルに達する見込み

2024年に13億米ドルと推定されるブルガダ症候群の世界市場は、2030年には19億米ドルに達し、分析期間2024-2030年のCAGRは7.5％で成長すると予測されます。本レポートで分析したセグメントの1つである心電図診断は、CAGR 8.2％を記録し、分析期間終了時には9億5,280万米ドルに達すると予測されます。心エコー図診断分野の成長率は、分析期間中CAGR 7.9%と推定されます。

米国市場は推定3億4,190万米ドル、中国はCAGR11.8％で成長予測

米国のブルガダ症候群市場は、2024年に3億4,190万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 11.8%で推移し、2030年には4億1,220万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.7%と7.3%と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界のブルガダ症候群市場- 主要動向と促進要因のまとめ

ブルガダ症候群が世界の心臓病治療および希少疾患治療の現場で注目を集める理由とは？

心臓突然死を伴うまれな遺伝性不整脈疾患であるブルガダ症候群は、世界の心臓病学および電気生理学の状況において、重要な重点領域として認識されつつあります。心電図（ECG）の異常パターンと心室細動のリスク上昇によって特徴づけられるこの疾患は、無症候性であることとエピソード性の発現であることから、しばしば過小診断されています。循環器専門医や救急医療従事者の意識が高まるにつれ、ブルガダ症候群患者の早期発見とリスク層別化が進み、診断ツール、遺伝子検査、致命的な不整脈イベントを予防する治療介入に対する需要が高まっています。

ブルガダ症候群が心臓突然死予防のプロトコールに含まれ、スポーツ心臓病学や家族性スクリーニングプログラムにおける認知度が高まるにつれ、ブルガダ症候群はより広範な遺伝性不整脈管理の枠組みの中に位置づけられるようになっています。この症候群は有病率が低いにもかかわらず、未診断または未治療の症例、特に発症率が高い東南アジアや南欧州の若年男性において死亡率が高い可能性があるため、戦略的に重要です。

診断、モニタリング、リスク層別化の進歩は、ブルガダ症候群管理をどのように改善しているか？

ブルガダ症候群の臨床管理は、正確な心電図解釈、挑発的薬物検査（ナトリウムチャネル遮断薬など）、SCN5Aやその他の関連遺伝子変異の次世代シーケンシングに大きく依存しています。心電図パターン認識ソフトウェア、携帯型モニタリング装置、電気生理学的マッピングの向上は、早期発見を助け、患者固有の介入計画を容易にします。また、AIによる心電図解析やウェアラブル心臓モニターは、間欠的なイベント検出や疑い例における長期的な評価をサポートしています。

失神歴、突然死の家族歴、電気生理学的検査中の誘発性、自発心電図パターンに基づくリスク層別化ツールは、植込み型除細動器（ICD）治療のための患者選択を精緻化しています。無症状または低リスクの患者では、継続的な観察と生活習慣の改善（発熱の抑制、薬剤の回避など）がケアの中心であることに変わりはないです。診断の精度が向上するにつれて、不整脈予防とQOLのバランスを考慮した個別化された管理決定が行われるようになってきています。

ブルガダ症候群診断・治療の需要はどこで伸びているのか、またどのような臨床現場で採用が進んでいるのか？

米国と西欧は、臨床インフラ、心遺伝学的サービス、ICDの採用という点で最も進んだ市場です。これらの地域の電気生理学センターと大学病院はスクリーニングと調査に積極的に関与しており、リスクベースの治療経路にブルガダ症候群を含める循環器ガイドラインに支えられています。アジア太平洋、特に日本、タイ、フィリピンでは、この疾患がより一般的になっており、地域の心臓病学会は死亡率を低下させるために心電図スクリーニングの拡大と早期介入プロトコルを推進しています。

主な臨床現場には、心臓電気生理学検査室、救急部、スポーツ心臓病クリニック、遺伝性不整脈治療室などがあります。需要は、原因不明の失神や心電図異常のある若年成人や、既知の遺伝子変異や突然死の既往歴のある家族に集中しています。また、小児循環器科では、リスクのある子供のブルガダパターンの早期スクリーニングへの関与が増加しています。ECGおよび遺伝学的サービスへの世界のアクセスが改善されるにつれて、より広範な患者の特定と早期の治療方針の決定が市場成長の原動力となっています。

ブルガダ症候群市場の世界的成長の促進要因は？

ブルガダ症候群の世界市場は、遺伝性不整脈に対する認識の高まり、診断方法の改善、高リスク患者へのICD使用の増加によって牽引されています。心臓突然死予防に関する一般市民や専門家の教育、心遺伝カウンセリングへのアクセス拡大、国の心臓検診プログラムへのブルガダ症候群の組み入れなどが、対応可能な人口を増加させています。

医療機器の革新、特に皮下ICDやリードレスペーシングシステムもまた、治療の受容性を高め、治療の負担を軽減しています。キニジンや新規抗不整脈薬のような薬理学的選択肢の調査は、機器治療の代替または補助療法を模索し続けています。世界の心臓病治療界が精密医療と積極的なリズム管理を受け入れる中、市場の軌跡を決定づける極めて重要な疑問があります。ブルガダ症候群管理は、多様なヘルスケアシステムにおいて、診断精度、予防的介入、長期的な患者の安全性のバランスをとる、スケーラブルでリスク調整可能なモデルへと進化できるだろうか？

セグメント

診断方法（心電図、心エコー図、電気生理学的検査およびマッピング、その他の診断方法）;治療タイプ（外科的方法、薬物療法）;適応症タイプ（ブルガダ1型、ブルガダ2型）;エンドユーザー（病院およびクリニック、外科センター、診断センター、その他のエンドユーザー）

調査対象企業の例（合計 34注目）

• Abbott Laboratories
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Boston Scientific Corporation
• Cadila Healthcare Ltd.
• Chiesi Farmaceutici S.p.A.
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Edwards Lifesciences Corporation
• Eli Lilly and Company
• GE Healthcare
• GeneDx
• GlaxoSmithKline plc（GSK）
• HeartSine Technologies LLC
• Johnson & Johnson
• LivaNova PLC
• Lupin Limited
• Medtronic plc

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Brugada Syndrome Market to Reach US$1.9 Billion by 2030

The global market for Brugada Syndrome estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Electrocardiogram Diagnosis, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$952.8 Million by the end of the analysis period. Growth in the Echocardiogram Diagnosis segment is estimated at 7.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$341.9 Million While China is Forecast to Grow at 11.8% CAGR

The Brugada Syndrome market in the U.S. is estimated at US$341.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$412.2 Million by the year 2030 trailing a CAGR of 11.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Brugada Syndrome Market - Key Trends & Drivers Summarized

Why Is Brugada Syndrome Gaining Attention in the Global Cardiac Care and Rare Disease Treatment Landscape?

Brugada Syndrome, a rare genetic arrhythmia disorder associated with sudden cardiac death, is increasingly recognized as a critical focus area within the global cardiology and electrophysiology landscape. Characterized by abnormal electrocardiogram (ECG) patterns and a heightened risk of ventricular fibrillation, the condition is often underdiagnosed due to its asymptomatic nature and episodic presentation. As awareness increases among cardiologists and emergency care providers, earlier identification and risk stratification of Brugada Syndrome patients is improving-driving demand for diagnostic tools, genetic testing, and therapeutic interventions that prevent fatal arrhythmic events.

Its inclusion in sudden cardiac death prevention protocols and growing visibility in sports cardiology and familial screening programs are positioning Brugada Syndrome within broader inherited arrhythmia management frameworks. Despite its low prevalence, the syndrome commands strategic importance due to its high mortality potential in undiagnosed or untreated cases, particularly among younger males in Southeast Asia and Southern Europe where incidence rates are elevated.

How Are Advancements in Diagnosis, Monitoring, and Risk Stratification Improving Brugada Syndrome Management?

Clinical management of Brugada Syndrome relies heavily on accurate ECG interpretation, provocative drug testing (e.g., with sodium channel blockers), and next-generation sequencing for SCN5A and other associated genetic mutations. Improvements in ECG pattern recognition software, portable monitoring devices, and electrophysiological mapping are aiding early detection and facilitating patient-specific intervention planning. AI-assisted ECG analytics and wearable cardiac monitors are also supporting intermittent event detection and longitudinal assessment in suspected cases.

Risk stratification tools-based on syncope history, family history of sudden death, inducibility during electrophysiology studies, and spontaneous ECG patterns-are refining patient selection for implantable cardioverter defibrillator (ICD) therapy. In asymptomatic or low-risk patients, ongoing observation and lifestyle modification (e.g., fever control, drug avoidance) remain central to care. As diagnostic precision improves, management decisions are increasingly being personalized to balance arrhythmia prevention with quality of life considerations.

Where Is Demand for Brugada Syndrome Diagnosis and Treatment Growing, and Which Clinical Settings Are Leading Adoption?

The United States and Western Europe represent the most advanced markets in terms of clinical infrastructure, cardiogenetic services, and ICD adoption. Electrophysiology centers and academic hospitals in these regions are actively involved in screening and research, supported by cardiology guidelines that include Brugada Syndrome in risk-based treatment pathways. In Asia-Pacific-particularly in Japan, Thailand, and the Philippines-the condition is more prevalent, and regional cardiology societies are promoting expanded ECG screening and early intervention protocols to reduce mortality rates.

Key clinical settings include cardiac electrophysiology labs, emergency departments, sports cardiology clinics, and inherited arrhythmia units. Demand is concentrated among young adults with unexplained syncope or abnormal ECGs, as well as families with known genetic mutations or sudden death history. Pediatric cardiology is also seeing increased involvement in early screening for Brugada patterns in at-risk offspring. As global access to ECG and genetic services improves, broader patient identification and earlier therapeutic decision-making are driving market growth.

What Is Fueling the Global Growth of the Brugada Syndrome Market?

The global Brugada Syndrome market is being driven by growing awareness of inherited cardiac arrhythmias, improvements in diagnostic modalities, and the increased use of ICDs in high-risk patients. Public and professional education on sudden cardiac death prevention, expanded access to cardiogenetic counseling, and the inclusion of Brugada Syndrome in national cardiac screening programs are collectively increasing the addressable population.

Medical device innovation, especially in subcutaneous ICDs and leadless pacing systems, is also enhancing treatment acceptability and reducing procedural burden. Research into pharmacologic options-such as quinidine and novel antiarrhythmic compounds-continues to explore alternatives or adjuncts to device therapy. As the global cardiac care community embraces precision medicine and proactive rhythm management, a pivotal question defines the market’s trajectory: Can Brugada Syndrome management evolve into a scalable, risk-tailored model that balances diagnostic accuracy, preventive intervention, and long-term patient safety across diverse healthcare systems?

SCOPE OF STUDY:

The report analyzes the Brugada Syndrome market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnosis Methods (Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping, Other Diagnosis Methods); Treatment Type (Surgical Methods, Drug Therapy); Indication Type (Brugada Type 1, Brugada Type 2); End-Use (Hospitals & Clinics, Surgical Centers, Diagnostic Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Boston Scientific Corporation
• Cadila Healthcare Ltd.
• Chiesi Farmaceutici S.p.A.
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Edwards Lifesciences Corporation
• Eli Lilly and Company
• GE Healthcare
• GeneDx
• GlaxoSmithKline plc (GSK)
• HeartSine Technologies LLC
• Johnson & Johnson
• LivaNova PLC
• Lupin Limited
• Medtronic plc

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Brugada Syndrome - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Availability of ECG Screening Enhances Early Detection Rates for Brugada Syndrome
  • Genetic Testing Integration Supports Family-Wide Risk Stratification in Brugada Diagnosis
  • ICD Implantation Remains the Standard for High-Risk Brugada Syndrome Management
  • Awareness Campaigns by Cardiac Associations Boost Recognition of Sudden Cardiac Death Risks
  • Expansion of Electrophysiology Labs Drives Demand for Specialized Brugada Management Protocols
  • Mapping-Guided Ablation Techniques Gain Traction as Adjunctive Therapy in Select Brugada Cases
  • Technological Advances in Wearable ECGs Enable Long-Term Monitoring in Suspected Brugada Patients
  • Global Disparities in Brugada Incidence Spur Regional Investment in Cardiac Genetics Infrastructure
  • Digital Clinical Decision Support Tools Improve Risk Assessment and Guideline Compliance
  • Integration of Brugada Syndrome Into SCD Screening Pathways Strengthens Institutional Preparedness
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Brugada Syndrome Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Brugada Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Brugada Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Brugada Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Electrocardiogram by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Electrocardiogram by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Electrocardiogram by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Echocardiogram by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Echocardiogram by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Echocardiogram by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Electrophysiological Testing & Mapping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Electrophysiological Testing & Mapping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Electrophysiological Testing & Mapping by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Diagnosis Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Diagnosis Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Diagnosis Methods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Surgical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Surgical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Surgical Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Surgical Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Surgical Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Surgical Methods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Drug Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Brugada Type 1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Brugada Type 1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Brugada Type 1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Brugada Type 2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Brugada Type 2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Brugada Type 2 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Brugada Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• JAPAN
  • Brugada Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• CHINA
  • Brugada Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• EUROPE
  • Brugada Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Brugada Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Brugada Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Brugada Syndrome by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• FRANCE
  • Brugada Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 104: France Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• GERMANY
  • Brugada Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Brugada Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 140: UK Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Brugada Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Brugada Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Brugada Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Brugada Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Brugada Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• INDIA
  • Brugada Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 215: India Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Brugada Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Brugada Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Brugada Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Brugada Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Brugada Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Brugada Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Brugada Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Brugada Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030
• AFRICA
  • Brugada Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Brugada Syndrome by Diagnosis Methods - Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Brugada Syndrome by Diagnosis Methods - Percentage Breakdown of Value Sales for Electrocardiogram, Echocardiogram, Electrophysiological Testing & Mapping and Other Diagnosis Methods for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Brugada Syndrome by End-Use - Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Brugada Syndrome by End-Use - Percentage Breakdown of Value Sales for Surgical Centers, Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Brugada Syndrome by Treatment Type - Surgical Methods and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Brugada Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Surgical Methods and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Brugada Syndrome by Indication Type - Brugada Type 1 and Brugada Type 2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Brugada Syndrome by Indication Type - Percentage Breakdown of Value Sales for Brugada Type 1 and Brugada Type 2 for the Years 2015, 2025 & 2030

IV. COMPETITION